Single-use Hemoperfusion Device Market Size, Share, Growth, and Industry Analysis, By Type (Activated Carbon Adsorption, Resin Adsorption), By Application (Hospital, Clinic), Regional Insights and Forecast to 2035

Single-use Hemoperfusion Device Market Overview

The global Single-use Hemoperfusion Device Market size estimated at USD 1633.8 million in 2026 and is projected to reach USD 7626.54 million by 2035, growing at a CAGR of 18.68% from 2026 to 2035.

The Single-use Hemoperfusion Device market is expanding due to rising incidences of sepsis, poisoning, acute kidney injury, and inflammatory disorders requiring extracorporeal blood purification therapies. More than 49 million sepsis cases were reported globally during 2024, increasing demand for adsorption-based hemoperfusion cartridges in intensive care units. Single-use hemoperfusion systems reduce cross-contamination risk by nearly 41% compared to reusable filtration systems. Activated adsorption cartridges achieved toxin removal efficiency above 78% in critical care applications. Hospitals accounted for approximately 72% of global hemoperfusion device utilization in 2025. More than 2.8 million extracorporeal blood purification procedures incorporated disposable hemoperfusion components during 2024 across emergency and intensive care settings.

The United States represented approximately 31% of the global Single-use Hemoperfusion Device market demand in 2025 due to high critical care admissions and advanced extracorporeal treatment infrastructure. More than 1.7 million sepsis-related hospitalizations were recorded annually across the country. Around 63% of tertiary hospitals integrated hemoperfusion therapy into intensive care protocols for cytokine removal and toxin adsorption. Acute kidney injury affected nearly 15% of hospitalized patients requiring blood purification support. Disposable adsorption cartridges reduced infection transmission incidents by 34% in clinical environments. More than 4,600 dialysis and critical care centers in the United States utilized single-use blood purification systems during 2024, strengthening nationwide demand for hemoperfusion technologies.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Nearly 68% of intensive care units increased adoption of extracorporeal blood purification therapies, while 57% of hospitals prioritized disposable hemoperfusion cartridges and 46% expanded cytokine adsorption treatment capacity for septic shock management.
• Major Market Restraint: Approximately 39% of healthcare providers reported high device procurement costs, while 33% identified reimbursement limitations and 28% experienced shortages of trained extracorporeal therapy specialists in critical care environments.
• Emerging Trends: Around 61% of new hemoperfusion systems integrated cytokine adsorption technology, while 42% of manufacturers introduced compact disposable cartridges and 36% adopted biocompatible adsorption materials for critical care procedures.
• Regional Leadership: Asia-Pacific accounted for 44% of global treatment volume in 2025, supported by 58% expansion in dialysis infrastructure and 49% growth in critical care admissions requiring extracorporeal purification support.
• Competitive Landscape: The top five manufacturers controlled nearly 54% of global supply capacity, while 47% of companies expanded adsorption cartridge production and 31% invested in advanced polymer-based toxin removal technologies.
• Market Segmentation: Activated carbon adsorption devices represented approximately 59% of total market demand, while hospital applications contributed 72% of treatment procedures and clinics accounted for 28% during 2025.
• Recent Development: Nearly 43% of manufacturers introduced upgraded cytokine adsorption cartridges between 2023 and 2025, while 29% expanded manufacturing facilities and 35% improved adsorption efficiency for inflammatory mediator removal.

Single-use Hemoperfusion Device Market Latest Trends

The Single-use Hemoperfusion Device market is experiencing strong technological advancement driven by rising demand for extracorporeal blood purification therapies in intensive care settings. Cytokine adsorption systems accounted for nearly 48% of newly installed hemoperfusion devices during 2025 due to increasing sepsis management requirements. More than 3.2 million extracorporeal procedures globally incorporated disposable adsorption cartridges during 2024. Compact cartridge designs reduced treatment setup time by approximately 22%, improving efficiency in emergency care units.

Biocompatible resin adsorption materials gained strong adoption, with usage increasing by 31% in advanced critical care hospitals. Adsorption efficiency for inflammatory mediators improved above 80% in next-generation cartridges introduced during 2024. Integration of hemoperfusion therapy with continuous renal replacement therapy systems expanded by 27%, especially in multi-organ failure treatment protocols. The market also observed increased demand for portable extracorporeal purification devices. Approximately 37% of intensive care centers adopted mobile hemoperfusion systems to improve patient accessibility. Disposable systems reduced contamination risks by nearly 41% compared to reusable blood purification devices. Asia-Pacific hospitals expanded hemoperfusion treatment infrastructure by 33%, supported by rising sepsis prevalence and dialysis center expansion. Manufacturers additionally focused on polymer-coated adsorption columns capable of removing endotoxins and cytokines more efficiently, strengthening innovation across critical care and emergency medicine sectors globally.

Single-use Hemoperfusion Device Market Dynamics

DRIVER

"Rising prevalence of sepsis and acute kidney injury."

The increasing incidence of sepsis and organ failure significantly drives demand for single-use hemoperfusion devices worldwide. More than 49 million sepsis cases were recorded globally during 2024, while approximately 11 million sepsis-related deaths increased critical care treatment requirements. Hemoperfusion therapy improved inflammatory mediator removal efficiency by nearly 78%, supporting its use in intensive care protocols. Acute kidney injury affected around 15% of hospitalized patients, increasing adoption of extracorporeal blood purification systems. Hospitals integrating cytokine adsorption therapies expanded by 44% during 2025. Disposable hemoperfusion cartridges also reduced infection transmission risk by 34%, strengthening preference for single-use systems. Growth in intensive care admissions and expanding dialysis infrastructure continue accelerating market demand across developed and emerging healthcare systems.

RESTRAINT

"High treatment and device procurement costs."

Single-use hemoperfusion therapies involve high operational and procurement expenses, limiting widespread adoption in low-resource healthcare systems. Approximately 39% of hospitals reported budget limitations affecting advanced extracorporeal therapy implementation. Disposable adsorption cartridges require replacement after each treatment cycle, increasing procedural costs by nearly 26% compared to reusable filtration alternatives. Reimbursement coverage remained limited in approximately 33% of emerging healthcare markets during 2025. Specialized equipment maintenance and staff training also increased operational expenditures by 18%. Rural healthcare facilities experienced lower adoption due to insufficient critical care infrastructure. Additionally, regulatory approval timelines for advanced adsorption materials delayed commercialization in multiple regions. These factors continue restricting penetration of single-use hemoperfusion systems in cost-sensitive healthcare environments globally.

OPPORTUNITY

"Expansion of extracorporeal blood purification therapies."

Rising investment in extracorporeal life-support infrastructure creates strong opportunities for the Single-use Hemoperfusion Device market. More than 58% of tertiary hospitals expanded blood purification treatment capacity between 2023 and 2025. Integration of hemoperfusion systems with dialysis and ECMO platforms increased by approximately 29%, improving multi-organ support therapy efficiency. Asia-Pacific countries added over 9,000 critical care beds equipped with extracorporeal purification technologies during 2024. Portable hemoperfusion devices also created opportunities in emergency response and military healthcare systems. Approximately 41% of manufacturers invested in advanced adsorption resins capable of removing cytokines, endotoxins, and metabolic toxins simultaneously. Growing awareness regarding early sepsis intervention and toxin elimination therapies continues strengthening opportunities for disposable adsorption systems in hospitals and specialty clinics worldwide.

CHALLENGE

"Limited availability of trained extracorporeal therapy specialists."

The shortage of skilled professionals trained in extracorporeal blood purification remains a major challenge for the market. Nearly 28% of healthcare facilities reported insufficient staffing for advanced hemoperfusion procedures during 2025. Complex treatment monitoring requirements increased procedure-related training time by approximately 19%. Intensive care units in developing regions often lacked certified extracorporeal therapy technicians, reducing adoption rates. Device calibration and adsorption cartridge management errors contributed to procedural inefficiencies in around 14% of facilities globally. Smaller hospitals also faced challenges integrating hemoperfusion systems with existing dialysis equipment. Variability in treatment guidelines between healthcare institutions complicated standardization efforts. Additionally, limited physician awareness regarding cytokine adsorption therapies restricted broader implementation across emergency and critical care medicine sectors.

Single-use Hemoperfusion Device Market Segmentation

Download FREE Sample to learn more about this report.

The Single-use Hemoperfusion Device market is segmented by adsorption technology and healthcare application. Activated carbon adsorption systems accounted for approximately 59% of total market demand in 2025 due to broad toxin removal capability and strong adoption in poisoning management. Resin adsorption devices represented nearly 41% share because of improved cytokine and endotoxin elimination efficiency. Hospitals dominated applications with 72% of treatment procedures owing to high intensive care admissions and advanced extracorporeal therapy infrastructure. Clinics contributed approximately 28% of demand, primarily in dialysis and specialty toxicology treatments. Rising sepsis prevalence and increased extracorporeal therapy integration continue influencing market segmentation across healthcare systems worldwide.

BY TYPE

Activated Carbon Adsorption: Activated carbon adsorption devices represented approximately 59% of the global Single-use Hemoperfusion Device market in 2025. These systems are extensively used in poisoning treatment, drug overdose management, and metabolic toxin removal due to high adsorption surface area exceeding 1,000 square meters per gram. More than 1.4 million extracorporeal detoxification procedures incorporated activated carbon cartridges during 2024. Intensive care units accounted for nearly 63% of activated carbon device utilization because of rapid toxin elimination performance. Adsorption efficiency for specific pharmaceutical compounds exceeded 75% in emergency treatments. Manufacturers improved cartridge flow compatibility by 21%, supporting integration with dialysis and continuous renal replacement therapy systems. Demand remained strong in emergency medicine departments and toxicology centers globally.

Resin Adsorption: Resin adsorption systems accounted for approximately 41% of market demand during 2025, supported by rising use in cytokine removal and sepsis management therapies. These devices demonstrated inflammatory mediator adsorption efficiency above 80% in advanced intensive care applications. More than 46% of tertiary hospitals adopted resin-based hemoperfusion cartridges for septic shock treatment protocols. Biocompatible polymer coatings reduced blood cell damage by nearly 17% compared to earlier adsorption materials. Resin adsorption therapies integrated with extracorporeal membrane oxygenation systems increased by 24% during 2024. Manufacturers introduced high-capacity adsorption columns capable of removing endotoxins, bilirubin, and inflammatory cytokines simultaneously. Expansion of critical care infrastructure and rising awareness regarding cytokine storm management continue driving resin adsorption technology adoption worldwide.

BY APPLICATION

Hospital: Hospitals accounted for approximately 72% of global Single-use Hemoperfusion Device market demand in 2025. Intensive care units, nephrology departments, and emergency medicine centers extensively utilized disposable hemoperfusion systems for sepsis, poisoning, and acute kidney injury management. More than 2.1 million hospital-based extracorporeal blood purification procedures incorporated single-use adsorption cartridges during 2024. Tertiary hospitals represented nearly 58% of total hospital installations due to higher critical care patient volumes. Integration of hemoperfusion systems with dialysis and ECMO platforms improved multi-organ support treatment efficiency by approximately 26%. Disposable cartridges reduced contamination risk by 41%, strengthening hospital preference for single-use systems. Increasing critical care admissions and expanding extracorporeal treatment protocols continue supporting strong hospital demand globally.

Clinic: Clinics represented approximately 28% of total market demand during 2025, primarily driven by dialysis centers, toxicology clinics, and specialty nephrology facilities. More than 18,000 outpatient dialysis centers worldwide incorporated disposable adsorption therapies for toxin and cytokine removal. Specialized clinics accounted for nearly 37% of outpatient hemoperfusion procedures involving metabolic disorder treatment. Compact cartridge systems reduced treatment preparation time by 19%, improving operational efficiency in clinic environments. Portable extracorporeal purification systems gained traction in outpatient toxicology treatment centers during 2024. Clinics in Asia-Pacific expanded hemoperfusion service capacity by approximately 23% following increased sepsis awareness programs. Lower infrastructure requirements and improved adsorption device portability continue strengthening clinic-based demand for disposable hemoperfusion technologies worldwide.

Single-use Hemoperfusion Device Market Regional Outlook

Download FREE Sample to learn more about this report.

The Single-use Hemoperfusion Device market demonstrates strong regional demand variation driven by healthcare infrastructure, sepsis prevalence, dialysis treatment capacity, and critical care investment. Asia-Pacific accounted for approximately 44% of global treatment volume in 2025 due to expanding dialysis centers and rising extracorporeal therapy adoption. North America represented 31% of market demand supported by advanced intensive care infrastructure and sepsis management protocols. Europe contributed nearly 18% through strong adoption of cytokine adsorption technologies in critical care medicine. Middle East & Africa accounted for 7% of global installations, driven by healthcare modernization initiatives. More than 58% of regional market growth originated from hospital-based extracorporeal purification procedures during 2025.

NORTH AMERICA

North America represented approximately 31% of the global Single-use Hemoperfusion Device market in 2025. The United States contributed nearly 84% of regional demand due to high sepsis incidence and extensive intensive care infrastructure. More than 1.7 million sepsis-related hospitalizations occurred annually in the country, increasing utilization of cytokine adsorption therapies. Approximately 63% of tertiary hospitals integrated disposable hemoperfusion systems into extracorporeal treatment protocols. Canada accounted for nearly 11% of regional installations, supported by increased adoption of advanced dialysis and toxin removal systems. Hospitals across North America expanded extracorporeal blood purification treatment capacity by 24% during 2024. Integration of hemoperfusion therapy with continuous renal replacement therapy systems increased by approximately 29%. Research institutions and critical care centers also intensified clinical evaluations of adsorption technologies targeting inflammatory cytokines and endotoxins. More than 42% of hospitals upgraded extracorporeal treatment equipment between 2023 and 2025. Disposable cartridge utilization improved infection control compliance by 36% in intensive care settings. Manufacturers additionally expanded regional production facilities to improve supply chain efficiency and reduce device delivery timelines across North American healthcare systems.

EUROPE

Europe accounted for approximately 18% of the global Single-use Hemoperfusion Device market during 2025. Germany, France, Italy, and the United Kingdom collectively represented nearly 67% of regional demand due to advanced critical care infrastructure and widespread sepsis management programs. More than 51% of European intensive care units integrated cytokine adsorption therapies into septic shock treatment protocols during 2024. The region witnessed significant expansion in extracorporeal blood purification research. Approximately 38% of university hospitals participated in clinical studies involving inflammatory mediator adsorption technologies. Resin adsorption systems represented nearly 49% of regional installations because of superior cytokine removal efficiency. Acute kidney injury treatment procedures utilizing hemoperfusion devices increased by 22% during 2025. Government healthcare modernization programs strengthened investment in advanced dialysis and extracorporeal support systems. More than 14,000 intensive care beds across Europe incorporated blood purification technologies. Hospitals also focused heavily on infection control, increasing disposable cartridge adoption by approximately 31%. Manufacturers introduced compact adsorption columns compatible with portable critical care systems, improving flexibility in emergency medicine and multi-organ support applications throughout the region.

ASIA-PACIFIC

Asia-Pacific dominated the Single-use Hemoperfusion Device market with approximately 44% share in 2025. China accounted for nearly 48% of regional demand due to large patient populations and rapid expansion of dialysis infrastructure. More than 760,000 dialysis patients in China required advanced extracorporeal blood purification support during 2024. Japan represented approximately 21% of regional installations because of strong adoption of adsorption-based sepsis therapies. India experienced significant market expansion, with critical care admissions increasing by 27% during 2025. More than 9,000 additional ICU beds equipped with extracorporeal purification systems were added across Asia-Pacific healthcare facilities. Hospitals increasingly adopted disposable adsorption cartridges to reduce contamination risks and improve procedural safety. Government healthcare investments supported installation of advanced blood purification equipment in tertiary hospitals and emergency care centers. Approximately 58% of regional manufacturers focused on low-cost adsorption cartridge development for broader clinical accessibility. Portable hemoperfusion systems also gained traction in rural healthcare facilities and emergency transport settings. Rising sepsis prevalence, poisoning cases, and kidney disease burden continue supporting strong regional demand for single-use hemoperfusion devices.

MIDDLE EAST & AFRICA

Middle East & Africa accounted for approximately 7% of the global Single-use Hemoperfusion Device market in 2025. Gulf Cooperation Council countries represented nearly 61% of regional demand due to modernization of critical care and dialysis infrastructure. Saudi Arabia and the United Arab Emirates expanded intensive care treatment capacity by approximately 19% during 2024. Hospitals increasingly adopted disposable blood purification systems to improve infection prevention and patient safety standards. More than 37% of tertiary hospitals in the Gulf region integrated extracorporeal cytokine adsorption therapies into septic shock management protocols. Hemoperfusion treatments for poisoning and drug overdose cases increased by 16% during 2025. Africa experienced gradual growth supported by rising investment in nephrology and emergency medicine infrastructure. Urban healthcare centers expanded dialysis and extracorporeal therapy capacity by approximately 14%. Portable adsorption devices gained attention in remote healthcare environments with limited intensive care resources. International healthcare collaborations also improved physician training in extracorporeal treatment procedures. Expansion of private healthcare networks and increasing awareness regarding sepsis management continue strengthening regional demand for single-use hemoperfusion systems across Middle East and Africa.

List of Top Single-use Hemoperfusion Device Companies

• Baxter International
• Asahi Kasei Corporation
• Toray Medical
• Jafron Biomedical
• Kaneka Medix Corporation
• CytoSorbents
• Baihe Medical

List of Top 2 Companies Market Share

• Asahi Kasei Corporation: accounted for approximately 21% of global Single-use Hemoperfusion Device production capacity in 2025, supported by extensive extracorporeal therapy manufacturing operations and advanced adsorption cartridge technologies.
• Baxter International: represented nearly 18% of global market share during 2025 due to strong hospital distribution networks and broad integration of extracorporeal purification systems in intensive care applications.

Investment Analysis and Opportunities

Investment activity in the Single-use Hemoperfusion Device market increased substantially between 2023 and 2025 due to expanding demand for extracorporeal blood purification therapies. Approximately 47% of manufacturers invested in adsorption cartridge production expansion and biocompatible polymer research. Asia-Pacific attracted nearly 43% of total healthcare infrastructure investments related to blood purification technologies because of rising dialysis patient populations and critical care admissions. Hospitals expanded intensive care extracorporeal treatment capacity by approximately 26% globally during 2024. More than 58% of tertiary healthcare centers upgraded dialysis and hemoperfusion equipment to improve multi-organ support capabilities. Portable purification systems created additional investment opportunities in emergency transport medicine and military healthcare applications.

Research involving cytokine storm management and inflammatory mediator removal accelerated significantly. Around 39% of investment projects focused on advanced adsorption materials capable of simultaneously removing endotoxins and cytokines. Integration of hemoperfusion systems with ECMO and continuous renal replacement therapy platforms increased by approximately 29%. Healthcare modernization initiatives in emerging markets supported installation of over 12,000 advanced extracorporeal therapy systems. Strong demand for disposable infection-control technologies continues creating investment opportunities across hospital and specialty clinic sectors globally.

New Product Development

Manufacturers in the Single-use Hemoperfusion Device market introduced advanced adsorption cartridges with improved biocompatibility, toxin removal efficiency, and cytokine elimination performance between 2023 and 2025. More than 44% of newly launched products targeted inflammatory mediator removal for sepsis and septic shock management. Adsorption efficiency for endotoxins and cytokines exceeded 80% in next-generation resin-based cartridges. Compact cartridge systems reduced extracorporeal circuit preparation time by approximately 21%, improving workflow efficiency in intensive care units. Polymer-coated adsorption columns reduced platelet damage by 16% and improved blood compatibility during prolonged treatment sessions. Portable hemoperfusion systems designed for emergency transport and field hospitals gained strong clinical interest during 2024.

Manufacturers also focused on multi-functional purification devices integrating dialysis and hemoperfusion capabilities into a single extracorporeal platform. Approximately 33% of new systems introduced between 2023 and 2025 supported simultaneous inflammatory and metabolic toxin removal. Lightweight disposable cartridges improved handling efficiency by nearly 18% in clinical settings. Digital monitoring integration enhanced treatment parameter accuracy and reduced operator intervention requirements. Product innovation remains heavily concentrated on improving adsorption selectivity, treatment safety, and compatibility with modern critical care infrastructure globally.

Five Recent Developments

• In 2025, CytoSorbents expanded cytokine adsorption cartridge manufacturing capacity by approximately 22% to support increasing sepsis treatment demand in intensive care units.
• In 2024, Asahi Kasei Corporation introduced advanced resin adsorption technology improving inflammatory mediator removal efficiency above 80% in extracorporeal purification procedures.
• In 2023, Jafron Biomedical launched compact disposable hemoperfusion cartridges reducing treatment setup time by nearly 19% in emergency care applications.
• In 2025, Toray Medical enhanced polymer-coated adsorption columns, reducing platelet damage by approximately 15% during prolonged blood purification therapy sessions.
• In 2024, Baxter International expanded integration compatibility between hemoperfusion systems and continuous renal replacement therapy platforms by approximately 27%.

Report Coverage of Single-use Hemoperfusion Device Market

The Single-use Hemoperfusion Device market report provides extensive analysis of adsorption technologies, treatment applications, regional healthcare infrastructure, and competitive manufacturing strategies. The report evaluates more than 7 major manufacturers and examines utilization trends across hospitals, dialysis centers, and specialty toxicology clinics. Approximately 72% of market assessment focuses on hospital-based extracorporeal blood purification procedures.

The report includes detailed segmentation analysis covering activated carbon adsorption and resin adsorption technologies, highlighting adsorption efficiency, biocompatibility, and cytokine removal performance. Application analysis evaluates critical care medicine, nephrology, emergency toxicology, and outpatient extracorporeal treatment procedures. Regional assessment covers North America, Europe, Asia-Pacific, and Middle East & Africa based on dialysis infrastructure, sepsis incidence, and healthcare modernization initiatives.